Reuters analysis talks about drug development for what they call “orphan diseases”, which are those relating to very small segments of the population.
Because only a small percentage of the population has these problems, drug companies have been able to charge what they like. Rare diseases therefore are attracting a lot of attention from various pharma players.
It seems though that health care providers are rebelling and the pressure is on to shake out pricing
Analysis: Entering the age of the $1 million medicine | Reuters.